Pacer Advisors
SYRE icon

Pacer Advisors’s Spyre Therapeutics SYRE Stock Holding History

Pacer Advisors’s Portfolio SYRE Stock Details SYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$55K Buy
+614
New +$44.8K ﹤0.01% 2015
2024
Q3 		– Sell
-382
Closed -$8.98K – 2694
2024
Q2 		$8.98K Buy
+382
New +$12.9K ﹤0.01% 3566

Other funds holding SYRE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Pacer Advisors's SYRE Position: Q2 2026 in Review

Pacer Advisors opened a new position in Spyre Therapeutics (SYRE) in Q2 2026: 614 shares worth $55K. The stake represents ﹤0.01% of the portfolio and ranks #2015 among its holdings. This is a return to the name: Pacer Advisors previously reported a position in SYRE as recently as Q2 2024.

Pacer Advisors first reported a position in SYRE in Q2 2024 and has held it in 2 quarters since. 267 funds tracked by Wall St. Rank hold SYRE as of Q2 2026.

  • Pacer Advisors held 614 shares of Spyre Therapeutics worth $55K as of Q2 2026.
  • Spyre Therapeutics was a new Pacer Advisors position in Q2 2026.
  • Spyre Therapeutics made up ﹤0.01% of Pacer Advisors's portfolio in Q2 2026, its #2015 holding.
  • Pacer Advisors first reported a position in Spyre Therapeutics in Q2 2024 and has held it in 2 quarters since.
  • 267 funds tracked by Wall St. Rank held Spyre Therapeutics as of Q2 2026.

Based on Pacer Advisors's 13F filing for Q2 2026, filed 13 Aug 2026.